TNFRSF17 and plasma cell myeloma: Additionally, Kochenderfer et al. developed a CAR T cell therapy targeted to B-cell maturation protein (BCMA), present in a majority of multiple myeloma (MM) cells, which resulted in a complete response in 50% of patients for this ongoing trial (181).